TCEAL6抗体TCEAL6一抗抗体Transcriptio
n elongation factor S-II protein-like 6 antibody抗体TCEAL6 Antibody抗体- ￥880 - 1320
- CUSABIO
- CN
- CSB-PA004246
- 2025年07月13日
- WB, ELISA; WB:1:500-1:2000, ELISA:1:10000
- Rabbit
- Human
企业认证
相关产品推荐更多 >
CX3CL1抗体CX3CL1兔多抗抗体X3CL1_HUMAN antibody抗体CX3CL1 Antibody抗体
￥440
tcyA抗体tcyA兔多抗抗体L-cystine-binding protein TcyA antibody抗体tcyA Antibody抗体
￥440
CD97抗体CD97一抗抗体CD antigen CD97抗体CD97 Antibody抗体
￥1100
RPL10A抗体RPL10A兔多抗抗体rpl10a antibody抗体RPL10A Antibody抗体
￥440
ABCE1抗体ABCE1一抗抗体RNS4I antibody抗体ABCE1 Antibody抗体
￥1100
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Synthesized peptide derived from the Internal region of Human TCEAL6.
- 亚型：
IgG
- 形态：
Liquid
- 保存条件：
Upon receipt, store at -20℃ or -80℃. Avoid repeated freeze.
- 克隆性：
/
- 标记物：
Non-conjugated
- 适应物种：
Human
- 保质期：
6个月
- 抗原来源：
Homo sapiens (Human)
- 目录编号：
Q6IPX3
- 级别：
优
- 库存：
200
- 供应商：
武汉华美生物工程有限公司
- 宿主：
Rabbit
- 应用范围：
WB, ELISA; WB:1:500-1:2000, ELISA:1:10000
- 浓度：
>95%,The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- 靶点：
TCEAL6
- 抗体英文名：
TCEAL6 Antibody
- 抗体名：
TCEAL6 antibody;Transcription elongation factor A protein-like 6 antibody;TCEA-like protein 6 antibody;Transcription elongation factor S-II protein-like 6 antibody
- 规格：
100μg/50μg
| 规格： | 100μg | 产品价格： | ￥1320.0 |
|---|---|---|---|
| 规格： | 50μg | 产品价格： | ￥880.0 |
保存缓冲液
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.功能
/风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Mapping Protein Distributions on Polytene Chromosomes by Immunostaining
secondary antibody. For double-labeling experiments, use fluorescence-conjugated secondary antibodies raised to the corresponding type of primary antibody. The dilution factor for each antibody needs to be determined experimentally. Blocking
cells. The catalytic domain of diphtheria toxin catalyzes the NAD+ -dependent ADP-ribosylation of the diphthamide residue in elongation factor 2, resulting in inhibition of protein synthesis (20 ,21 ). As the delivery of a single molecule
【翻译】Development trends for monoclonal antibody cancer therapeutics
has more than tripled since the 1980s, from 4.3 per year in the 1980s to 8.3 per year in the 1990s and 13.3 per year for 2000–2005. One reason for the increased investment in mAbs was the evolution of the discovery technology. The initial method for producing mAbs
技术资料暂无技术资料 索取技术资料
